IndraLab

Statements

Arsenous acid activates KCNH2. 2 / 2
| 2
reach
"In contrast to other drugs, which result in blockade via binding to specific sites within the channel, arsenic trioxide appears to produce hERG liability by inhibition of ion-channel trafficking resulting in reduced channel expression on the cell surface."
17520054
reach
"This man was positive for both the KCNQ1 p.L353L variant and the KCNH2 p.K897T variant, but had been treated with arsenic trioxide, a chemotherapeutic agent which is also a potent QT prolonging drug."
28264985